Arvee Laboratories (India)（ARVEE）株式概要Arvee Laboratories (India) Ltd.は、インド国内外で様々な特殊化学品を製造・販売している。 詳細ARVEE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績4/6財務の健全性5/6配当金0/6報酬過去1年間で収益は17.6%増加しました リスク分析過去5年間で収益は年間15%減少しました。 意味のある収益がありません ( ₹322M )意味のある時価総額がありません ( ₹2B )すべてのリスクチェックを見るARVEE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹163.68197.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0613m2016201920222025202620282031Revenue ₹179.7mEarnings ₹14.1mAdvancedSet Fair ValueView all narrativesArvee Laboratories (India) Ltd. 競合他社Cochin Minerals and RutileSymbol: BSE:513353Market cap: ₹2.1bMahickra ChemicalsSymbol: NSEI:MAHICKRAMarket cap: ₹1.9bVikas EcotechSymbol: BSE:530961Market cap: ₹1.9bChembond Material TechnologiesSymbol: BSE:530871Market cap: ₹2.3b価格と性能株価の高値、安値、推移の概要Arvee Laboratories (India)過去の株価現在の株価₹163.6852週高値₹290.7852週安値₹129.11ベータ0.531ヶ月の変化-0.66%3ヶ月変化5.60%1年変化-0.72%3年間の変化52.54%5年間の変化46.80%IPOからの変化423.78%最新ニュースReported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).最新情報をもっと見るRecent updatesReported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Additional Director Shalini Jalan was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.15 (vs ₹0.85 in 1Q 2025)First quarter 2026 results: EPS: ₹0.15 (down from ₹0.85 in 1Q 2025). Revenue: ₹76.5m (down 28% from 1Q 2025). Net income: ₹1.69m (down 82% from 1Q 2025). Profit margin: 2.2% (down from 8.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.お知らせ • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025.New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹391m revenue, or US$4.6m). Market cap is less than US$100m (₹1.95b market cap, or US$22.8m).Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹150, the stock trades at a trailing P/E ratio of 75.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 92% over the past three years.Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.22 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (down from ₹0.22 in 3Q 2024). Revenue: ₹89.1m (up 16% from 3Q 2024). Net income: ₹1.55m (down 35% from 3Q 2024). Profit margin: 1.7% (down from 3.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.分析記事 • Jan 12Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 28%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 28% after a relatively good...New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 2.5% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₹370m revenue, or US$4.4m). Market cap is less than US$100m (₹2.49b market cap, or US$29.4m).分析記事 • Nov 21Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 25%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 25% after a relatively good...Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.89 (vs ₹0.19 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.89 (up from ₹0.19 in 2Q 2024). Revenue: ₹126.8m (up 42% from 2Q 2024). Net income: ₹9.81m (up 366% from 2Q 2024). Profit margin: 7.7% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.85 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹0.85 (up from ₹0.44 in 1Q 2024). Revenue: ₹107.1m (up 41% from 1Q 2024). Net income: ₹9.42m (up 93% from 1Q 2024). Profit margin: 8.8% (up from 6.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.お知らせ • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024, at 11:30 Indian Standard Time.お知らせ • Mar 27Arvee Laboratories (India) Ltd. Announces Resignation of Mr. Dipen Dalal as Independent DirectorArvee Laboratories (India) Ltd. informed that Mr. Dipen Dalal, - Independent Director of the company has tendered his resignation vide letter dated March 26, 2024. He will be cease to be a Director of the company with effect from 26th March, 2024.Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.84 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.22 (down from ₹0.84 in 3Q 2023). Revenue: ₹78.9m (down 52% from 3Q 2023). Net income: ₹2.38m (down 74% from 3Q 2023). Profit margin: 3.0% (down from 5.7% in 3Q 2023). The decrease in margin was driven by lower revenue.New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Revenue is less than US$5m (₹369m revenue, or US$4.4m). Market cap is less than US$100m (₹1.39b market cap, or US$16.7m).Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹1.86 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.19 (down from ₹1.86 in 2Q 2023). Revenue: ₹90.0m (down 60% from 2Q 2023). Net income: ₹2.11m (down 90% from 2Q 2023). Profit margin: 2.3% (down from 9.0% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 26+ 3 more updatesArvee Laboratories (India) Ltd. to Report Q4, 2024 Results on May 30, 2024Arvee Laboratories (India) Ltd. announced that they will report Q4, 2024 results on May 30, 2024Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹1.03 in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (down from ₹1.03 in 1Q 2023). Revenue: ₹76.9m (down 58% from 1Q 2023). Net income: ₹4.87m (down 57% from 1Q 2023). Profit margin: 6.3% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Aug 08Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹124, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 519% over the past three years.Reported Earnings • May 08Full year 2023 earnings released: EPS: ₹4.43 (vs ₹2.34 in FY 2022)Full year 2023 results: EPS: ₹4.43 (up from ₹2.34 in FY 2022). Revenue: ₹697.9m (up 73% from FY 2022). Net income: ₹41.2m (up 60% from FY 2022). Profit margin: 5.9% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹106, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 7.3% over the past year.分析記事 • Apr 13Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹0.84 (vs ₹0.48 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.84 (up from ₹0.48 in 3Q 2022). Revenue: ₹162.5m (up 106% from 3Q 2022). Net income: ₹9.21m (up 73% from 3Q 2022). Profit margin: 5.7% (down from 6.8% in 3Q 2022). The decrease in margin was driven by higher expenses.分析記事 • Dec 22Do Arvee Laboratories (India)'s (NSE:ARVEE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹160, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 97% over the past year.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹115, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 44% over the past year.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year.分析記事 • Sep 16We Ran A Stock Scan For Earnings Growth And Arvee Laboratories (India) (NSE:ARVEE) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Aug 03First quarter 2023 earnings released: EPS: ₹1.03 (vs ₹0.48 in 1Q 2022)First quarter 2023 results: EPS: ₹1.03 (up from ₹0.48 in 1Q 2022). Revenue: ₹182.0m (up 101% from 1Q 2022). Net income: ₹11.4m (up 116% from 1Q 2022). Profit margin: 6.3% (up from 5.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 14Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022, at 11:30 Indian Standard Time. Location: Registered Office of the Company situated at 403, Entice Nr. Jayantilal Park BRTS, Iskcon-Bopal Road Ahemdabad Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2022 and Statement of Profit and Loss and Cash Flow Statement for the year ended on 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto; to reappoint Mr. Shalin Bharatbhai Chokshi a Director of the Company who retires by rotation and being eligible offers himself for re-appointment; to appoint statutory auditor of the Company.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹90.15, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 206% over the past three years.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹66.20, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 124% over the past three years.Reported Earnings • May 28Full year 2022 earnings released: EPS: ₹2.34 (vs ₹2.43 in FY 2021)Full year 2022 results: EPS: ₹2.34 (down from ₹2.43 in FY 2021). Revenue: ₹407.9m (down 14% from FY 2021). Net income: ₹25.7m (down 3.9% from FY 2021). Profit margin: 6.3% (up from 5.7% in FY 2021). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹88.80, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 50% over the past year.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹92.90, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 238% over the past three years.Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.48 (down from ₹1.39 in 3Q 2021). Revenue: ₹79.0m (down 60% from 3Q 2021). Net income: ₹5.34m (down 65% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 20x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹74.90, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 158% over the past three years.Executive Departure • Sep 23Independent Director Paragbhai Shah has left the companyOn the 16th of September, Paragbhai Shah's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Paragbhai's name. Paragbhai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹89.00, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.分析記事 • Aug 13Subdued Growth No Barrier To Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) PriceArvee Laboratories (India) Ltd.'s ( NSE:ARVEE ) price-to-earnings (or "P/E") ratio of 42.6x might make it look like a...Reported Earnings • Jul 18First quarter 2022 earnings released: EPS ₹0.48 (vs ₹0.91 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹91.2m (up 1.0% from 1Q 2021). Net income: ₹5.29m (up 5.2% from 1Q 2021). Profit margin: 5.8% (up from 5.6% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jun 20Full year 2021 earnings released: EPS ₹2.43 (vs ₹2.02 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹479.6m (up 5.6% from FY 2020). Net income: ₹26.8m (up 20% from FY 2020). Profit margin: 5.6% (up from 4.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹122, the stock trades at a trailing P/E ratio of 60.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹159, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years.分析記事 • Apr 19Calculating The Intrinsic Value Of Arvee Laboratories (India) Ltd. (NSE:ARVEE)Today we will run through one way of estimating the intrinsic value of Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) by...株主還元ARVEEIN ChemicalsIN 市場7D5.3%0.3%0.5%1Y-0.7%-2.9%-0.5%株主還元を見る業界別リターン: ARVEE過去 1 年間で-2.9 % の収益を上げたIndian Chemicals業界を上回りました。リターン対市場: ARVEEは、過去 1 年間で-0.5 % のリターンをもたらしたIndianマーケットと一致しました。価格変動Is ARVEE's price volatile compared to industry and market?ARVEE volatilityARVEE Average Weekly Movement8.0%Chemicals Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: ARVEE 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ARVEEの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201270Shalin Patelarveelabs.comアーヴェ・ラボラトリーズ(インド)社は、インド国内外で様々な特殊化学品を製造・販売している。同社は、5-ソジオイソフタル酸ジメチル、5-スルホイソフタル酸モノナトリウム塩、5-スルホイソフタル酸モノリチウム塩、5-ソジオイソフタル酸ビス-（β-ヒドロキシエチル）イソフタル酸などのポリマー改質剤を提供しています；および造影剤中間体、例えば5-ニトロイソフタル酸、5-ニトロイソフタル酸ジメチル、5-ニトロイソフタル酸モノメチル、5-ヒドロキシイソフタル酸、5-アミノイソフタル酸、5-アミノイソフタル酸ジメチル、ならびに3,5-ジニトロ安息香酸および3,5-ジアミノ安息香酸。また、2-アセチルチオフェン、チオフェン-2-カルボキシアルデヒド、4-アミノピリジン、2-クロロ-5-ニトロ安息香酸からなる医薬品中間体も提供している。また、製品の輸出も行っている。Arvee Laboratories (India) Ltd.は2012年に設立され、インドのアーメダバードを拠点としている。もっと見るArvee Laboratories (India) Ltd. 基礎のまとめArvee Laboratories (India) の収益と売上を時価総額と比較するとどうか。ARVEE 基礎統計学時価総額₹1.80b収益（TTM）₹25.26m売上高(TTM)₹321.95m71.4xPER（株価収益率5.6xP/SレシオARVEE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ARVEE 損益計算書（TTM）収益₹321.95m売上原価₹146.64m売上総利益₹175.32mその他の費用₹150.05m収益₹25.26m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）2.29グロス・マージン54.45%純利益率7.85%有利子負債／自己資本比率3.3%ARVEE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 19:16終値2026/05/25 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Arvee Laboratories (India) Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026
Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).
New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).
Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026
Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).
New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).
Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Additional Director Shalini Jalan was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.15 (vs ₹0.85 in 1Q 2025)First quarter 2026 results: EPS: ₹0.15 (down from ₹0.85 in 1Q 2025). Revenue: ₹76.5m (down 28% from 1Q 2025). Net income: ₹1.69m (down 82% from 1Q 2025). Profit margin: 2.2% (down from 8.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
お知らせ • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025.
New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹391m revenue, or US$4.6m). Market cap is less than US$100m (₹1.95b market cap, or US$22.8m).
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹150, the stock trades at a trailing P/E ratio of 75.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 92% over the past three years.
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.22 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (down from ₹0.22 in 3Q 2024). Revenue: ₹89.1m (up 16% from 3Q 2024). Net income: ₹1.55m (down 35% from 3Q 2024). Profit margin: 1.7% (down from 3.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
分析記事 • Jan 12Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 28%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 28% after a relatively good...
New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 2.5% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₹370m revenue, or US$4.4m). Market cap is less than US$100m (₹2.49b market cap, or US$29.4m).
分析記事 • Nov 21Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 25%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 25% after a relatively good...
Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.89 (vs ₹0.19 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.89 (up from ₹0.19 in 2Q 2024). Revenue: ₹126.8m (up 42% from 2Q 2024). Net income: ₹9.81m (up 366% from 2Q 2024). Profit margin: 7.7% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.85 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹0.85 (up from ₹0.44 in 1Q 2024). Revenue: ₹107.1m (up 41% from 1Q 2024). Net income: ₹9.42m (up 93% from 1Q 2024). Profit margin: 8.8% (up from 6.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
お知らせ • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024, at 11:30 Indian Standard Time.
お知らせ • Mar 27Arvee Laboratories (India) Ltd. Announces Resignation of Mr. Dipen Dalal as Independent DirectorArvee Laboratories (India) Ltd. informed that Mr. Dipen Dalal, - Independent Director of the company has tendered his resignation vide letter dated March 26, 2024. He will be cease to be a Director of the company with effect from 26th March, 2024.
Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.84 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.22 (down from ₹0.84 in 3Q 2023). Revenue: ₹78.9m (down 52% from 3Q 2023). Net income: ₹2.38m (down 74% from 3Q 2023). Profit margin: 3.0% (down from 5.7% in 3Q 2023). The decrease in margin was driven by lower revenue.
New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Revenue is less than US$5m (₹369m revenue, or US$4.4m). Market cap is less than US$100m (₹1.39b market cap, or US$16.7m).
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹1.86 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.19 (down from ₹1.86 in 2Q 2023). Revenue: ₹90.0m (down 60% from 2Q 2023). Net income: ₹2.11m (down 90% from 2Q 2023). Profit margin: 2.3% (down from 9.0% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 26+ 3 more updatesArvee Laboratories (India) Ltd. to Report Q4, 2024 Results on May 30, 2024Arvee Laboratories (India) Ltd. announced that they will report Q4, 2024 results on May 30, 2024
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹1.03 in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (down from ₹1.03 in 1Q 2023). Revenue: ₹76.9m (down 58% from 1Q 2023). Net income: ₹4.87m (down 57% from 1Q 2023). Profit margin: 6.3% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Aug 08Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹124, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 519% over the past three years.
Reported Earnings • May 08Full year 2023 earnings released: EPS: ₹4.43 (vs ₹2.34 in FY 2022)Full year 2023 results: EPS: ₹4.43 (up from ₹2.34 in FY 2022). Revenue: ₹697.9m (up 73% from FY 2022). Net income: ₹41.2m (up 60% from FY 2022). Profit margin: 5.9% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹106, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 7.3% over the past year.
分析記事 • Apr 13Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.
Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹0.84 (vs ₹0.48 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.84 (up from ₹0.48 in 3Q 2022). Revenue: ₹162.5m (up 106% from 3Q 2022). Net income: ₹9.21m (up 73% from 3Q 2022). Profit margin: 5.7% (down from 6.8% in 3Q 2022). The decrease in margin was driven by higher expenses.
分析記事 • Dec 22Do Arvee Laboratories (India)'s (NSE:ARVEE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹160, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 97% over the past year.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹115, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 44% over the past year.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year.
分析記事 • Sep 16We Ran A Stock Scan For Earnings Growth And Arvee Laboratories (India) (NSE:ARVEE) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Aug 03First quarter 2023 earnings released: EPS: ₹1.03 (vs ₹0.48 in 1Q 2022)First quarter 2023 results: EPS: ₹1.03 (up from ₹0.48 in 1Q 2022). Revenue: ₹182.0m (up 101% from 1Q 2022). Net income: ₹11.4m (up 116% from 1Q 2022). Profit margin: 6.3% (up from 5.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 14Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022, at 11:30 Indian Standard Time. Location: Registered Office of the Company situated at 403, Entice Nr. Jayantilal Park BRTS, Iskcon-Bopal Road Ahemdabad Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2022 and Statement of Profit and Loss and Cash Flow Statement for the year ended on 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto; to reappoint Mr. Shalin Bharatbhai Chokshi a Director of the Company who retires by rotation and being eligible offers himself for re-appointment; to appoint statutory auditor of the Company.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹90.15, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 206% over the past three years.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹66.20, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 124% over the past three years.
Reported Earnings • May 28Full year 2022 earnings released: EPS: ₹2.34 (vs ₹2.43 in FY 2021)Full year 2022 results: EPS: ₹2.34 (down from ₹2.43 in FY 2021). Revenue: ₹407.9m (down 14% from FY 2021). Net income: ₹25.7m (down 3.9% from FY 2021). Profit margin: 6.3% (up from 5.7% in FY 2021). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹88.80, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 50% over the past year.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹92.90, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 238% over the past three years.
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.48 (down from ₹1.39 in 3Q 2021). Revenue: ₹79.0m (down 60% from 3Q 2021). Net income: ₹5.34m (down 65% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 20x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹74.90, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 158% over the past three years.
Executive Departure • Sep 23Independent Director Paragbhai Shah has left the companyOn the 16th of September, Paragbhai Shah's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Paragbhai's name. Paragbhai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹89.00, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.
分析記事 • Aug 13Subdued Growth No Barrier To Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) PriceArvee Laboratories (India) Ltd.'s ( NSE:ARVEE ) price-to-earnings (or "P/E") ratio of 42.6x might make it look like a...
Reported Earnings • Jul 18First quarter 2022 earnings released: EPS ₹0.48 (vs ₹0.91 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹91.2m (up 1.0% from 1Q 2021). Net income: ₹5.29m (up 5.2% from 1Q 2021). Profit margin: 5.8% (up from 5.6% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jun 20Full year 2021 earnings released: EPS ₹2.43 (vs ₹2.02 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹479.6m (up 5.6% from FY 2020). Net income: ₹26.8m (up 20% from FY 2020). Profit margin: 5.6% (up from 4.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹122, the stock trades at a trailing P/E ratio of 60.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹159, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years.
分析記事 • Apr 19Calculating The Intrinsic Value Of Arvee Laboratories (India) Ltd. (NSE:ARVEE)Today we will run through one way of estimating the intrinsic value of Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) by...
